Adverum Biotechnologies - ADVM Forward Price-to-Revenue Multiple

Corporate emblem and logo of Adverum Biotechnologies (ADVM)

The stable management of Adverum Biotechnologies (ADVM) has established the foundation for the final stages of trials, which supports the issuer's forward P/S. The company aims to capture the ocular gene therapy niche through its Ixo-vec drug. The prospect of replacing frequent injections for AMD with a single shot makes the asset an attractive M&A target, and 90.80 becomes the new metric value determining the business's market valuation.

Adverum Biotechnologies Inc. - ADVM Market Cap to Future Revenue Ratio (period 05/21/2023 - 11/13/2025)

Metric breakdowns and analytics for Adverum Biotechnologies Inc. (ADVM)

- current price and projected stock value:
Analysis of all company metrics:Adverum Biotechnologies, Inc. (ADVM)
Manufactured products of Adverum Biotechnologies, Inc.

Forward P/S measures the market value of a business relative to its expected sales volume, allowing investors to assess the degree of optimism priced in between reporting periods. By analyzing the expected P/S multiple, one can evaluate the extent to which the market has priced the success of Adverum Biotechnologies (ADVM) gene therapy clinical expansion and the completion of Phase II/III trials into the company's current capitalization.